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Fat meets the cholinergic antiinﬂammatory pathway
 
Kevin J. Tracey
 
The cholinergic antiinflammatory pathway is a neural mechanism that is 
controlled by the vagus nerve and inhibits local cytokine release, thereby 
preventing the damaging effects of cytokine overproduction. A new study now 
shows that dietary fat can activate this pathway, a finding that may help 
explain the immune system’s failure to react to food antigens and commensal 
bacteria. Here we discuss this new data and its potential implications for 
dietary intervention in the treatment of inflammatory diseases.
 
The cytokine theory of disease
 
Cytokines underlie the clinical manifes-
tations of many pathological and clinical
syndromes ranging from shock and se-
vere sepsis to arthritis and inflammatory
bowel disease. The “cytokine theory of
disease” originated in the 1970s and 80s
and stemmed from basic biological and
physiological studies of body weight,
temperature regulation, and blood pres-
sure (1). Early investigators established
that the proinflammatory cytokine tumor
necrosis factor (TNF) was both necessary
and sufficient to cause the pathophysio-
logical response to acute bacterial infec-
tion, and that administration of mono-
clonal anti-TNF antibodies prevented
shock and lethal tissue damage. This
prompted a shift in scientific focus from
developing therapies that directly target
pathogens to those that target products
of the immune system, such as TNF.
The effectiveness of these therapies in
the clinic validated the cytokine theory
of disease in humans and proved that it is
possible to rationally control the cytokine
response to clinical advantage.
The cytokine response to infection
or injury is a well-orchestrated and
tightly controlled process (2). When
functioning properly, cytokines success-
fully eradicate pathogenic invaders and
then restore homeostasis. Sometimes
cytokines are overproduced, however,
either because the magnitude of the inva-
sive stimulus is overwhelming or because
the counterregulatory mechanisms that
normally restrain cytokine release break
down. For instance, high levels of bac-
terial endotoxin in the blood, as occur
in patients with fulminant meningo-
coccemia, activate the immune system
to release large amounts of TNF, which
in turn causes a lethal septic shock syn-
drome (3). Not all infections or injuries
cause this burst of TNF production;
some are associated with a different cy-
tokine response pattern. For instance,
patients with intraperitoneal infection
with 
 
Escherichia coli
 
 can develop epithe-
lial cell dysfunction and lethal organ
damage caused by excessive production
of the inflammatory nuclear protein
high mobility group box-1 (HMGB1),
a syndrome termed severe sepsis (4).
Thus, in order to effectively exploit our
mechanistic and therapeutic knowledge
of cytokines it is important to recog-
nize the fundamental differences in the
pathological and biological activity of
different cytokines in distinct clinical
syndromes. For example, anti-TNF an-
tibodies might be effective in prevent-
ing acute septic shock syndrome but
ineffective in preventing severe sepsis
(5); anti-HMGB1 antibodies might ef-
fectively prevent the organ damage
and lethality of severe sepsis but would
not be expected to be useful in cases of
acute septic shock (1, 4, 6). These ex-
amples highlight two important con-
cepts. First, health is dependent on a
controlled cytokine response, and sec-
ond, knowledge about the mechanisms
that normally restrain the cytokine re-
sponse can be exploited to develop
new therapeutics.
 
Keeping cytokines in check
 
Redundant antiinflammatory mecha-
nisms normally restrain the cytokine re-
sponse. Glucocorticoids, antiinflam-
matory cytokines (such as interleukin
[IL]-10 and transforming growth factor
[TGF]-
 
 
 
), hormones (such as melano-
cyte-stimulating hormone), and other
metabolic products (such as spermine)
all inhibit cytokine release. Antiinflam-
matory cytokines are released by mac-
rophages, lymphocytes, and other cells
of the immune system during the earli-
est stages of infection or injury and are
delivered to the local site of inflamma-
tion by diffusion through tissues or by
way of the bloodstream (1, 2). Their ac-
tivities reduce the likelihood that a local
inflammatory response will spill over
into the blood and impair distant organ
function. A major limitation of this hu-
moral antiinflammatory system, how-
ever, is that it can cause immunosup-
pression. Thus, an infected wound in
the palm of one hand may increase cir-
culating levels of glucocorticoids and
IL-10 to immunosuppressive levels that
render the patient susceptible to other
infections. Recently, my colleagues and
I discovered that the central nervous
system is hard wired to control the cy-
tokine response independently of the
humoral antiinflammatory response (7).
This mechanism inhibits cytokine re-
lease locally in tissues, without causing
systemic immunosuppression.
 
The cholinergic 
antiinflammatory pathway
 
The vagus nerve, a paired structure that
arises in the brainstem and traverses the
neck, thorax, and abdomen to inner-
vate visceral organs, is named for its
wandering and meandering course. Its
fibers contain sensory and motor com-
ponents that control organ functions as
varied as heart rate and digestion. In
addition to controlling these classic
physiological functions, we recently
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discovered that the vagus nerve pre-
vents the release of TNF, HMGB1, IL-1,
and other proinflammatory cytokines
(7). As the activity of this pathway is
controlled by neural signals, it provides
a way for the brain to regulate the
cytokine response in a localized, con-
trolled, and organ-specific manner.
The neurotransmitter acetylcholine
is released by vagus nerve endings and
binds to nicotinic 
 
 
 
7 receptors on
macrophages and other cytokine-pro-
ducing cells in organs such as the
spleen, liver, and heart (8). Ligation of
nicotinic receptors by acetylcholine in-
hibits cytokine synthesis and release by
preventing the activation and nuclear
translocation of NF-
 
 
 
B, and by stimu-
lating the antiinflammatory JAK3-SOCS3
pathway (Fig. 1) (8–10). Expression of
nicotinic 
 
 
 
7 receptors is required for
the vagus nerve to interface with the
immune system, as elimination of the
gene that encodes this receptor in mice
abolishes the vagus nerve control of the
cytokine response (8). This vagus nerve–
controlled counterregulatory system,
termed the “cholinergic antiinflamma-
tory pathway,” controls cytokine syn-
thesis by resident macrophages in the
reticuloendothelial system. This path-
way suppresses cytokine activity lo-
cally in specific sites, thereby prevent-
ing the release of disease-inducing
cytokines into blood.
 
The inflammatory reflex
 
The cholinergic antiinflammatory path-
way is the efferent arm of the inflam-
matory reflex (7). IL-1, endotoxin, and
other inflammatory products activate
afferent signals in the vagus nerve,
which serves as a sensor of inflamma-
tion or injury. This information is re-
layed to the central nervous system via
the hypothalamic–pituitary axis and
triggers the release of acetylcholine
from efferent vagus nerve endings. The
vagus nerve is anatomically positioned
to inhibit cytokine production in the
organs of the reticuloendothelial sys-
tem. It may be possible to exploit the
inflammatory reflex to therapeutic ad-
vantage. We and others have explored
the effects of stimulating the vagus
nerve using pace maker–like devices
that have been safely implanted in
thousands of patients with seizure dis-
orders (10–14).
Preclinical animal studies have
shown that vagus nerve stimulators are
extremely effective in suppressing cy-
tokine-mediated inflammation and
damage in endotoxemia, severe sepsis,
hemorrhagic shock, ischemia reperfu-
sion injury, arthritis, and postopera-
tive ileus (7–14). These experiments
reveal a central regulatory role for va-
gus nerve activity in suppressing cyto-
kine release in organs and in serum,
and correspondingly in attenuating dis-
ease severity in response to a variety of
inflammatory stimuli. A second exper-
imental strategy has been to develop
agonists for the 
 
 
 
7 nictotinic receptor
as experimental therapeutics. Agents
from this class effectively inhibit
HMGB1, TNF, and other proinflam-
matory cytokines in animals models of
Figure 1. Activation of the vagus nerve leads to the release of acetylcholine (Ach) that 
binds to  -7 nicotinic receptors ( 7 nAChR) on cytokine producing cells. This inhibits the activation 
of NF- B and activates STAT3 phosphorylation. Phosphorylated STAT3 triggers an antiinflammatory 
signal by increasing SOCS3 expression, which suppresses signaling from cytokine receptors. Together, 
these signals prevent the release of TNF, HMGB1, and other cytokines implicated in the pathogenesis 
of inflammatory disease.
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endotoxemia, severe sepsis, hemmor-
rhagic shock, ileus, and experimental
diabetes (7, 9).
 
Dietary fat and the cholinergic 
antiinflammatory pathway
 
On page 1023 of this issue, Luyer et
al.  (15) present compelling evidence
that consumption of fat in the diet can
activate the cholinergic antiinflamma-
tory pathway (15). They found that ad-
ministration of high fat nutrition re-
duced circulating levels of TNF and
IL-6 in rats subjected to hemorrhagic
shock, a manipulation known to acti-
vate high blood cytokine levels. When
these experiments were repeated in an-
imals subjected to vagotomy, the ad-
ministration of the high fat diet no
longer prevented the increase in TNF
and IL-6. The authors also revealed a
mechanistic role for cholecystokinin
(CCK), a neuropeptide released after
consumption of dietary fat that triggers
several digestive functions including
stimulation of gall bladder contraction
and exocrine pancreas secretion, and
activation of afferent vagus nerve sig-
nals that induce satiety. Administration
of CCK receptor antagonists to rats fed
a high fat diet impaired the fat-induced
suppression of TNF and IL-6 during
hemorrhagic shock. Luyer et al. also
explored the effects of administering a
nicotinic receptor antagonist (chlori-
sondamine) on the dietary fat-induced
regulation of cytokines (15). Nicotine
receptor antagonism blocked the ability
of dietary fat to suppress TNF and
IL-6, which, when considered together
with the vagotomy experiments, indi-
cates that the intake of dietary fat sup-
presses cytokine release by activating
the cholinergic antiinflammatory path-
way (15). These provocative findings
are important for at least two reasons
that are discussed below. First, this
pathway may help explain why the tril-
lions of microorganisms that reside in
the human intestines do not stimulate
an exaggerated cytokine response. Sec-
ond, these data open up several possi-
bilities for new clinical studies involv-
ing nutritional manipulation of the
cytokine response.
 
Trillions of microbes, 
but no inflammation
 
A fundamental unanswered question in
immunology and physiology is why the
enormous intestinal reservoir of mi-
crobes, and their associated endo- and
enterotoxins fail to activate an inflam-
matory cytokine response. The gut is a
major source of blood cytokines in hu-
mans subjected to i.v. endotoxin infu-
sion, indicating that the enteric im-
mune system is capable of producing a
cytokine response (16). This contrasts
with the absence of cytokine produc-
tion or an inflammatory response in the
bowel wall, which is adjacent to the
endotoxin-rich gut lumen. Intact
food  proteins, bacterial products, and
other antigens can cross the epithelium
through intermittent openings in the
tight junction, and interact with mac-
rophages and other cytokine-producing
cells in the lamina propria, with in-
traepithelial lymphocytes, and with T
and B cells in the Peyer’s patches (for
review see reference 17). But, under
normal circumstances, these interac-
tions fail to trigger an inflammatory re-
sponse. There is growing evidence that
cytokine-mediated inflammation in the
gut is prevented in part by regulatory T
(T reg) cells. T reg cells produce antiin-
flammatory mediators, including TGF-
 
 
 
and IL-10, that inhibit cytokine synthe-
sis (17). Luyer’s results (15) now also
raise the possibility that cholinergic sig-
nals from the enteric nervous system
may also help suppress local inflamma-
tory responses to commensal microbes.
The localized release of acetylcho-
line from the enteric nervous system
will likely suppress cytokine production
by macrophages and dendritic cells in
response to commensal bacteria. Dys-
function of this pathway would be ex-
pected to trigger the development of
inflammatory bowel disease or other
inflammatory diseases of the gut. This
model is supported by data showing
that nicotine is therapeutic for some
patients with ulcerative colitis (18), a
disease characterized by excessive co-
lonic cytokine production. This effect
is likely due to nicotine binding to re-
ceptors on gut immune cells, thus
mimicking the efferent cholinergic an-
tiinflammatory pathway and suppress-
ing cytokine production. Nicotine is
not effective, however, in Crohn’s dis-
ease, an inflammatory bowel disease
that is responsive to anti-TNF therapy.
A possible explanation for disparate ef-
fects of nicotine on ulcerative colitis
and Crohn’s disease is that the former
could be caused by an acquired defect
in acetylcholine production; such a de-
fect could be reversed by exogenous
nicotine. In contrast, Crohn’s disease
might not result from a problem in ace-
tylcholine production, but rather from
a defect in the nicotinic receptor or a
signaling abnormality that interferes
with the ability of cytokine-producing
cells to respond to acetylcholine. In this
setting, nicotine would be useless.
Consistent with this idea, clinical stud-
ies have shown that administration of
fish oil is therapeutic in patients with
ulcerative colitis, but not in those with
Crohn’s disease (19). The study by
Luyer et al. suggests the possibility that
these protective effects are dependent
on fat-induced activation of the cholin-
ergic antiinflammatory pathway (15).
There are many unknowns in this
pathway that remain to be addressed.
One unknown is whether different
types of dietary fat vary in their ability
to activate the cholinergic antiinflam-
matory pathway. It is also possible that
diet-induced activation of the cholin-
ergic antiinflammatory pathway under-
lies the beneficial effects of early enteral
feeding in trauma and surgery patients,
which significantly reduces mortality
from sepsis and organ damage (20).
 
Clinical correlates
 
Advances in molecular biology and an-
imal physiology have helped us to
study human inflammatory diseases
with the hope of applying this knowl-
edge to the development of new thera-
pies. For this approach to succeed, it
will be important to identify surrogate
markers and end points for monitoring
the activity of the cholinergic pathway
in the clinic. A generally accepted
method of measuring vagus nerve ac-
tivity, or “tone,” is to calculate the in-
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stantaneous heart rate variability using
software that measures the variations in
time between individual heart beats, as
detected by electrocardiographic re-
cording. Although it is not currently
known whether vagus nerve activity in
the heart correlates with the activation
of the cholinergic antiinflammatory
pathway in humans, there have been
reports of decreased vagus nerve activ-
ity in diseases associated with exagger-
ated cytokine responses. Patients with
severe sepsis, rheumatoid arthritis, lu-
pus, and inflammatory bowel disease
have all been shown to have significant
decreases in their instantaneous heart
rate variability (21–24). An underlying
defect in the activity of the cholinergic
antiinflammatory pathway might trig-
ger an overproduction of cytokines in
response to an otherwise innocuous
immunological stimulus and thus con-
tribute to disease pathogenesis.
Animal studies indicate that the
threshold of vagus nerve activity that
activates the cholinergic antiinflamma-
tory pathway is significantly lower than
that required to activate a change in in-
stantaneous heart rate heart variability.
If this proves to be the case in humans,
then patients with decreased instanta-
neous heart rate variability might be
predicted to be at increased risk for de-
veloping cytokine-mediated diseases.
We need to learn more about these po-
tential relationships, which theoreti-
cally could be studied in the context of
clinical trials of dietary fat supplemen-
tation in patients with inflammatory
diseases, an approach that has already
shown significant therapeutic effects in
some studies (25–29). For example,
Holguin and colleagues recently re-
ported that supplementing the diet of
elderly patients with either fish oil, or
soy oil, significantly increased instanta-
neous heart rate variability (25). Their
study did not address the relationship
between these changes in vagus nerve
activity and inflammatory markers, but
the results indicate the feasibility of ap-
proaching this question in the future.
Studies could also be performed to re-
veal whether different types of dietary
fat are more potent activators of the
cholinergic antiinflammatory pathway,
and thus more effective for the treat-
ment of patients with rheumatoid ar-
thritis or inflammatory bowel disease,
two cytokine-driven diseases may re-
spond to ingestion of dietary fat.
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